H.C. Wainwright reiterates Ionis stock rating on Zanvastro approval

Ionis Pharmaceuticals gained a key catalyst after FDA approval of Zanvastro (zilganersen) for Alexander disease, arriving 19 days before the Sept. 22 PDUFA date. H.C. Wainwright reiterated a Buy rating and lifted its price target to $115 (vs. $58.13), implying nearly 100% upside, after increasing its approval probability to 100% from 75%. While analysts do not expect Ionis to be profitable this year (shares trade at a high P/B of 21.97), the approval and elevated likelihood profile should support positive re-rating into upcoming milestones (e.g., Oct. 26 bepirovirsen PDUFA and HORIZON Phase 3 updates in H2 2026).

Analysis

The market should treat this as a sentiment and de-risking event, not a fundamental re-rate by itself. For IONS, the value is less the near-zero contribution of this single rare-disease asset and more the signal that the platform still converts into approvable drugs, which matters for how investors underwrite the broader late-stage pipeline and any future partnering economics. That said, the stock already carries multiple layers of optionality, so the approval is more likely to compress the bear case than justify a fresh wholesale re-rating.

The second-order issue is commercialization quality: a small-population launch can produce headline revenue but still fail to move enterprise value if uptake, reimbursement, and physician adoption are uneven. The real watch item is whether management can translate the approval into a cleaner narrative for the self-commercialized products and the upcoming readouts; otherwise the market will keep valuing IONS as a high-duration biotech with execution risk, not as a de-risked asset. The voucher is useful for non-dilutive economics, but it is not a substitute for durable cash flow.

Contrarian view: the setup may already be too consensually bullish on pipeline breadth while underestimating the valuation burden. If the next catalyst cycle does not show tangible commercial acceleration, the stock can give back the approval pop quickly, especially because biotech multiples are still sensitive to funding and risk appetite. Falsifier on the upside is a sustained move above the prior post-approval gap with follow-through into the next label/launch catalyst; downside is any evidence that launch math or payer coverage disappoints over the next 1-3 months.

Key Decisions for Investors

• Avoid chasing IONS on the first-day approval reaction; use any 5-10% retracement over the next 1-2 weeks to reassess versus upcoming bepirovirsen and commercial catalysts.
• Pair trade: long IONS / short XBI or IBB for 1-3 months if you want to own platform de-risking while hedging broad biotech beta; thesis fails if IONS underperforms on launch commentary or the sector rerates harder on rates.
• If already long, trim 20-30% into strength and hold the remainder only for the October PDUFA and 2H26 HORIZON readout; the approval alone does not justify full position size given valuation and profitability risk.
• Set a watch level around the post-news breakout zone: if IONS cannot hold gains for 3-5 sessions, treat the move as a sentiment spike and rotate capital into higher-conviction biotech names with nearer-term revenue inflection.
• For new risk, consider call spreads instead of outright stock only if the next catalyst window opens: upside is driven by multiple expansion, but the risk/reward is poor if the market discounts this approval as already priced.